Carlos Tristan is the acting director of the Stem Cell Translation Laboratory (SCTL) within NCATS’ Division of Preclinical Innovation. Tristan works on leveraging multi-omic technologies to develop and optimize induced pluripotent stem cell culture maintenance and differentiation protocols to accelerate the translational application of iPSC-derived cells in disease modeling, regenerative therapy and drug discovery.
Tristan joined the SCTL in 2016, serving as a staff scientist and helping to establish chemical, robotic, high-throughput and multi-omic platforms to address current hurdles in the iPSC field. Prior to joining NCATS, Tristan conducted his postdoctoral work at the Radiation Oncology Branch of the National Cancer Institute’s Center for Cancer Research in Bethesda, Maryland, where he focused on understanding the molecular mechanisms of tumor-initiating cells in glioblastoma multiforme.
Tristan earned his doctorate in cellular and molecular medicine from the Johns Hopkins University School of Medicine, where he worked in the Department of Psychiatry and Behavioral Sciences under Akira Sawa, M.D., Ph.D., to uncover novel signaling mechanisms and crosstalk among cell stress-signaling cascades. Tristan earned his Master of Science in biology and two Bachelor’s degrees in chemistry and biology from California State University in Fresno, California.
Tristan is interested in developing robust and scalable protocols for the maintenance and differentiation of iPSCs for high-throughput screening assays and clinical applications.